
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2170806/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. Clinical Infectious Diseases, 2023, 76, e426-e438.	5.8	23
2	Case Report: Atypical Manifestations Associated With FOXP3 Mutations. The "Fil Rouge―of Treg Between IPEX Features and Other Clinical Entities?. Frontiers in Immunology, 2022, 13, 854749.	4.8	6
3	Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors. International Journal of Molecular Sciences, 2022, 23, 7155.	4.1	31
4	Dysregulation in Bâ€cell responses and T follicular helper cell function in ADA2 deficiency patients. European Journal of Immunology, 2021, 51, 206-219.	2.9	29
5	CD38 downregulation modulates NAD+ and NADP(H) levels in thermogenic adipose tissues. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158819.	2.4	18
6	Transcription Factor Evaluation by Flow Cytometry. Methods in Molecular Biology, 2021, 2285, 35-47.	0.9	1
7	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient—A Case Study. Open Forum Infectious Diseases, 2021, 8, ofab217.	0.9	64
8	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. PLoS Pathogens, 2021, 17, e1009448.	4.7	43
9	Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28â^' T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer. Cancers, 2021, 13, 2234.	3.7	8
10	Characterization of T lymphocytes in severe COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 5608-5613.	5.0	24
11	Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunology, Immunotherapy, 2021, 70, 3679-3692.	4.2	15
12	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Frontiers in Immunology, 2021, 12, 704110.	4.8	22
13	Increased frequency of interleukinâ€4 and reduced frequency of interferonâ€Î³ and ILâ€17â€producing CD4+ and CD8+ cells in scleromyxedema. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1092-1097.	2.4	8
14	Identification, Purification and Molecular Characterization of Chondrosin, a New Protein with Anti-tumoral Activity from the Marine Sponge Chondrosia Reniformis Nardo 1847. Marine Drugs, 2020, 18, 409.	4.6	9
15	PO-183 Pilot study on immunomodulation role of radiotherapy in oropharyngeal cancer: preliminary results. Radiotherapy and Oncology, 2019, 132, 96-97.	0.6	0
16	Dopamine inhibits human CD8+ Treg function through D1-like dopaminergic receptors. Journal of Neuroimmunology, 2019, 332, 233-241.	2.3	24
17	THU0505â€INTRINSIC AND EXTRINSIC B CELL DEFECT IN DADA2 PATIENTS. , 2019, , .		0
18	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. Journal of Virus Eradication, 2019, 5, 47-49.	0.5	0

#	Article	IF	CITATIONS
19	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. Journal of Virus Eradication, 2019, 5, 47-49.	0.5	0
20	The Ligurian HIV Network: How Medical Informatics Standards Can Help Clinical Research. Studies in Health Technology and Informatics, 2019, 264, 1666-1667.	0.3	0
21	White matter microstructure alterations correlate with terminally differentiated CD8+ effector T cell depletion in the peripheral blood in mania: Combined DTI and immunological investigation in the different phases of bipolar disorder. Brain, Behavior, and Immunity, 2018, 73, 192-204.	4.1	30
22	CD8+CD28â^'CD127loCD39+ regulatory T-cell expansion: AÂnew possible pathogenic mechanism for HIV infection?. Journal of Allergy and Clinical Immunology, 2018, 141, 2220-2233.e4.	2.9	22
23	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. Frontiers in Immunology, 2018, 9, 2447.	4.8	1
24	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naÃ ⁻ ve, HIV-1-infected patients. HIV Clinical Trials, 2018, 19, 158-162.	2.0	2
25	Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma. Blood, 2018, 132, 4598-4598.	1.4	2
26	Glutathione and the switch of aerobic metabolism collaborate for multi-drug resistance of neuroblastoma. Free Radical Biology and Medicine, 2017, 108, S69.	2.9	0
27	A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response. Scientific Reports, 2017, 7, 6286.	3.3	46
28	Phenotypic Alterations Involved in CD8+ Treg Impairment in Systemic Sclerosis. Frontiers in Immunology, 2017, 8, 18.	4.8	15
29	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. Journal of Immunology Research, 2017, 2017, 1-13.	2.2	29
30	AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. Oncotarget, 2016, 7, 60872-60884.	1.8	8
31	Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib. PLoS ONE, 2016, 11, e0152465.	2.5	45
32	Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma. Oncotarget, 2016, 7, 70715-70737.	1.8	40
33	Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence. Oncotarget, 2016, 7, 6424-6435.	1.8	22
34	Abstract A020: The analyses of immune infiltrate and gene expression of MAGE antigens in bladder cancer allow to explain and predict recurrence. , 2016, , .		0
35	Abstract B127: Free DNA and tolerance. , 2016, , .		0
36	Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system. HIV Clinical Trials, 2015, 16, 190-196.	2.0	7

#	Article	IF	CITATIONS
37	Nanoparticles increase the efficacy of cancer chemopreventive agents in cells exposed to cigarette smoke condensate. Carcinogenesis, 2015, 36, 368-377.	2.8	17
38	Early and repeated IgG1Fc-pCons chimera vaccinations (GX101) improve the outcome in SLE-prone mice. Clinical and Experimental Medicine, 2015, 15, 255-260.	3.6	5
39	Impaired immune response to Candida albicans in cells from Fanconi anemia patients. Cytokine, 2015, 73, 203-207.	3.2	5
40	lmmunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. Human Vaccines and Immunotherapeutics, 2015, 11, 838-850.	3.3	26
41	Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL. Journal of the International AIDS Society, 2014, 17, 19718.	3.0	2
42	Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients. Aids, 2014, 28, 1071-1074.	2.2	5
43	Single nucleotide polymorphisms in the promoter regions of Foxp3 and ICOSLG genes are associated with Alopecia Areata. Clinical and Experimental Medicine, 2014, 14, 91-97.	3.6	33
44	Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity. Cancer Immunology, Immunotherapy, 2014, 63, 501-511.	4.2	21
45	HO-1 up-regulation: A key point in high-risk neuroblastoma resistance to bortezomib. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 613-622.	3.8	46
46	Prevention of Lymphocyte Neurotoxic Effects by microRNA Delivery. MicroRNA (Shariqah, United Arab) Tj ETQc	0 0 0 rgBT 1.2	/Ovgrlock 10
47	ImmunoDB: a web based tool to analyze preclinical data. Studies in Health Technology and Informatics, 2014, 205, 438-42.	0.3	2
48	Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. Journal of Translational Medicine, 2013, 11, 120.	4.4	18
49	Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. Journal of Neurolmmune Pharmacology, 2013, 8, 1106-1113.	4.1	69
50	A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1041-1052.	4.2	55
51	CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes. Cancer Immunology, Immunotherapy, 2013, 62, 851-862.	4.2	56
52	Indoleamine 2,3 dioxygenase gene polymorphisms correlate with CD8+ Treg impairment in systemic sclerosis. Human Immunology, 2013, 74, 166-169.	2.4	24
53	Metformin selectively affects human glioblastoma tumor-initiating cell viability. Cell Cycle, 2013, 12, 145-156.	2.6	154
54	Multicentre clinical trials' data management: a hybrid solution to exploit the strengths of electronic data capture and electronic health records systems. Informatics for Health and Social Care, 2013, 38, 313-329.	2.6	19

#	Article	IF	CITATIONS
55	Generation of more effective cancer vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 2543-2547.	3.3	11
56	The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials. Medicine 2 0, 2013, 2, e5.	2.4	22
57	Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmunity Reviews, 2012, 12, 300-304.	5.8	70
58	The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. FASEB Journal, 2012, 26, 1251-1260.	0.5	81
59	Cyclophosphamide inhibits the generation and function of CD8+ regulatory T cells. Human Immunology, 2012, 73, 207-213.	2.4	27
60	Abscisic acid ameliorates the systemic sclerosis fibroblast phenotype in vitro. Biochemical and Biophysical Research Communications, 2012, 422, 70-74.	2.1	19
61	Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1. Free Radical Biology and Medicine, 2012, 52, 488-496.	2.9	40
62	CD8 ⁺ T regulatory/suppressor cells and their relationships with autoreactivity and autoimmunity. Autoimmunity, 2011, 44, 51-57.	2.6	42
63	Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clinical Immunology, 2011, 139, 249-257.	3.2	105
64	Th17 cells and allergic rhinitis: Is there clinical relevance?. Otolaryngology - Head and Neck Surgery, 2010, 143, 604-605.	1.9	8
65	The role of AIRE polymorphisms in melanoma. Clinical Immunology, 2010, 136, 96-104.	3.2	23
66	Th1/Th17 gammadelta T cells are expanded in HIV-1 infected patients and respond to Candida albicans. Retrovirology, 2010, 7, .	2.0	0
67	Expansion of vdelta1 T lymphocytes reactive to c. albicans IN HIV-1 infected patients: effect of influenza virus vaccine. Retrovirology, 2010, 7, .	2.0	0
68	Relevance of CD38 Expression on CD8 T Cells to Evaluate Antiretroviral Therapy Response in HIV-1-infected Youths. Scandinavian Journal of Immunology, 2010, 71, 45-51.	2.7	14
69	Peripheral TH-17 Cells in Children with Allergic Rhinitis: Preliminary Report. International Journal of Immunopathology and Pharmacology, 2010, 23, 379-382.	2.1	6
70	Elispot and Elisa Assessment of Interferon-Gamma after Sublingual Immunotherapy. European Journal of Inflammation, 2010, 8, 31-35.	0.5	5
71	365 ANALYSIS OF REGULATORY T CELLS IN PATIENTS AFFECTED BY RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.4	0
72	Crosstalk between decidual NK and CD14 ⁺ myelomonocytic cells results in induction of Tregs and immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11918-11923.	7.1	220

#	Article	lF	CITATIONS
73	Peripheral Th-17 cells in allergic rhinitis: New evidence. International Immunopharmacology, 2010, 10, 226-229.	3.8	34
74	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 176-180.	6.5	64
75	Serum Il-17 after one Course of Sublingual Immunotherapy in Allergic Rhinitis to Birch. European Journal of Inflammation, 2009, 7, 49-51.	0.5	9
76	Serum Leptin Levels in Patients with Pollen-Induced Allergic Rhinitis. International Archives of Allergy and Immunology, 2009, 148, 211-218.	2.1	20
77	Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone. Clinical and Experimental Immunology, 2009, 158, 55-63.	2.6	1
78	Serum interleukinâ€17 levels are related to clinical severity in allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1375-1378.	5.7	116
79	Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine, 2009, 27, 3367-3372.	3.8	34
80	Adipokines and sublingual immunotherapy: Preliminary report. Human Immunology, 2009, 70, 73-78.	2.4	7
81	Vδ1 T lymphocytes producing IFN-γ and IL-17 are expanded in HIV-1–infected patients and respond to Candida albicans. Blood, 2009, 113, 6611-6618.	1.4	153
82	Antigen-presenting function of human peritoneum mesothelial cells. Clinical and Experimental Immunology, 2008, 101, 172-176.	2.6	44
83	Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-Î ³ production after sublingual immunotherapy in patients with allergic rhinitis. Human Immunology, 2008, 69, 409-413.	2.4	24
84	Advancements on phenotypic and functional characterization of non–antigen-specific CD8+CD28â^' regulatory T cells. Human Immunology, 2008, 69, 745-750.	2.4	44
85	Carry-over effect on IFN-gamma production induced by allergen-specific immunotherapy. International Immunopharmacology, 2008, 8, 1622-1625.	3.8	12
86	867 IMPAIRMENT OF CD8+CD28- T SUPPRESSOR CELL FUNCTION IN PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2008, 48, S325-S326.	3.7	1
87	Serum IL-17 levels in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2008, 122, 650-651.e2.	2.9	52
88	Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults. Vaccine Journal, 2008, 15, 253-259.	3.1	64
89	Assessment of humoral and cell-mediated immunity against <i>Bordetella pertussis</i> in adolescent, adult, and senior subjects in Italy. Epidemiology and Infection, 2008, 136, 1576-1584.	2.1	16
90	Patients with Allergic Rhinitis Show an Allergen-Specific Interferon-Gamma Defect. European Journal of Inflammation, 2008, 6, 87-91.	0.5	6

#	Article	IF	CITATIONS
91	CD8+CD28â^' T Regulatory Lymphocytes Inhibiting T Cell Proliferative and Cytotoxic Functions Infiltrate Human Cancers. Journal of Immunology, 2007, 179, 4323-4334.	0.8	207
92	Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases. Current Medicinal Chemistry, 2007, 14, 3166-3170.	2.4	19
93	Sublingual immunotherapy: An update on immunologic and functional effects. Allergy and Asthma Proceedings, 2007, 28, 40-43.	2.2	25
94	Sublingual immunotherapy-induced IL-10 production is associated with changed response to the decongestion test: Preliminary results. Allergy and Asthma Proceedings, 2007, 28, 574-577.	2.2	5
95	Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: Preliminary reports. International Immunopharmacology, 2006, 6, 1370-1373.	3.8	28
96	Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood, 2006, 107, 1505-1512.	1.4	55
97	Sublingual immunotherapy and regulatory T cells. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 511-513.	5.7	19
98	Endocrine Regulation of Suppressor Lymphocytes: Role of the Glucocorticoid-Induced TNF-Like Receptor. Annals of the New York Academy of Sciences, 2006, 1069, 377-385.	3.8	12
99	Non-Antigen-Specific CD8+ T Suppressor Lymphocytes in Diseases Characterized by Chronic Immune Responses and Inflammation. Annals of the New York Academy of Sciences, 2005, 1050, 115-123.	3.8	45
100	Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Annals of Allergy, Asthma and Immunology, 2005, 95, 38-44.	1.0	115
101	Non-antigen specific CD8+ T suppressor lymphocytes. Clinical and Experimental Medicine, 2004, 4, 86-92.	3.6	46
102	Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28â^' T cells and inhibit both T-Cell proliferation and CTL function. Human Immunology, 2004, 65, 142-156.	2.4	151
103	Migration of Vδ1 and Vδ2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1–infected patients: competition by HIV-1 Tat. Blood, 2004, 103, 2205-2213.	1.4	120
104	Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and participating in the development of anti-inflammatory functional behavior of phagocytic macrophages. Human Immunology, 2003, 64, 9-20.	2.4	10
105	Preservation of clonal heterogeneity of the Pneumocystis carinii -specific CD4 T cell repertoire in HIV infected, asymptomatic individuals. Clinical and Experimental Immunology, 2002, 128, 155-162.	2.6	7
106	Analysis of the antigen specific T cell repertoires in HIV infection. Immunology Letters, 2001, 79, 85-91.	2.5	7
107	Genetically modified immunocompetent cells in HIV infection. Gene Therapy, 2001, 8, 1593-1600.	4.5	5
108	Natural Analogue Peptides of an HIV-1 GP120 T-Helper Epitope Antagonize Response of GP120-Specific Human CD4 T-Cell Clones. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 1-7.	2.1	9

#	Article	IF	CITATIONS
109	Natural Analogue Peptides of an HIV-1 GP120 T-Helper Epitope Antagonize Response of GP120-Specific Human CD4 T-Cell Clones. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 1-7.	2.1	10
110	Cd4+ T cell response to leishmania spp. in non-infected individuals. Human Immunology, 2000, 61, 531-537.	2.4	8
111	T Helper Cells Specific for Retroviral Epitopes. , 1999, , 89-97.		0
112	Loci influencing development of Th responses. Identification from in vitro analysis. Microbes and Infection, 1999, 1, 79-88.	1.9	7
113	Rational reconstitution of the immune repertoire in AIDS with autologous, antigen-specific, in vitro-expanded CD4 lymphocytes. Immunology Letters, 1999, 66, 117-120.	2.5	7
114	Antagonistic activity of HIV-1 T helper peptides flanked by an unrelated carrier protein. European Journal of Immunology, 1999, 29, 1448-1455.	2.9	6
115	Antagonistic activity of HIV-1 T helper peptides flanked by an unrelated carrier protein. European Journal of Immunology, 1999, 29, 1448-1455.	2.9	Ο
116	AttenuatedListeria monocytogenescarrier strains can deliver an HIV-1 gp120 T helper epitope to MHC class II-restricted human CD4+ T cells. European Journal of Immunology, 1998, 28, 1807-1814.	2.9	20
117	A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. Clinical and Experimental Immunology, 1998, 111, 186-192.	2.6	18
118	Repertoire Breadth of Human CD4+ T Cells Specific for HIV gp120 and p66 (Primary Antigens) or for PPD and Tetanus Toxoid (Secondary Antigens). Human Immunology, 1998, 59, 137-148.	2.4	19
119	Requirement for Different Presenting Cells and for Different Processing Mechanisms by Human CD4 T Helper Clones Specific for M. tuberculosis Antigens. Human Immunology, 1998, 59, 265-274.	2.4	3
120	Recognition of Antigenic Clusters of Candida albicans by T Lymphocytes from Human Immunodeficiency Virus-Infected Persons. Journal of Infectious Diseases, 1998, 178, 488-496.	4.0	29
121	Anti-HIV genetic treatment of antigen-specific human CD4 lymphocytes for adoptive immunotherapy of opportunistic infections in AIDS. Gene Therapy, 1997, 4, 1216-1224.	4.5	16
122	Handling of retroviral antigens by human antigen-presenting cells. Research in Virology, 1996, 147, 97-101.	0.7	1
123	Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection. European Journal of Immunology, 1996, 26, 2461-2469.	2.9	29
124	Human T leukaemia virus type 1 (HTLVâ€1) specific Tâ€helper cell response: clonal fluctuations and repertoire heterogeneity. British Journal of Haematology, 1996, 93, 287-294.	2.5	6
125	Human T helper cells specific for HIV reverse transcriptase: possible role in intrastructural help for HIV envelope-specific antibodies. European Journal of Immunology, 1995, 25, 1217-1223.	2.9	16
126	Recognition of human T-leukemia virus (HTLV-1) envelope by human CD4+ T- cell lines from HTLV-1 seronegative individuals: specificity and clonal heterogeneity. Blood, 1995, 85, 1547-1554.	1.4	22

#	Article	IF	CITATIONS
127	Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. Italian Journal of Neurological Sciences, 1994, 15, 49-53.	0.1	6
128	Quantitative analysis of peripheral allergen-specific B lymphocytes in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1994, 49, 348-353.	5.7	2
129	Human T-helper cell recognition of an immunodominant epitope of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. Vaccine, 1994, 12, 1071-1077.	3.8	54
130	Role of flanking variable sequences in antigenicity of consensus regions of HIV gp120 for recognition by specific human T helper clones. European Journal of Immunology, 1993, 23, 269-274.	2.9	24
131	Frequency of allergen-specific T lymphocytes in blood and bronchial response to allergen in asthma. Journal of Allergy and Clinical Immunology, 1993, 91, 1075-1081.	2.9	44
132	Quality Control in Immunophenotyping Annals of the New York Academy of Sciences, 1993, 677, 417-419.	3.8	2
133	Circulating Lymphocyte Subsets after Total Lymphoid Irradiation in Chronic Progressive Multiple Sclerosis. Annals of the New York Academy of Sciences, 1993, 677, 458-461.	3.8	0
134	Non-covalent complexes of HIV gp120 with CD4 and/or mAbs enhance activation of gp120-specific T clones and provide intermolecular help for anti-CD4 antibody production. International Immunology, 1993, 5, 1109-1117.	4.0	21
135	Kinetic immunodominance: functionally competing antibodies against exposed and cryptic epitopes of Escherichia coli β-galactosidase are produced in time sequence. International Immunology, 1992, 4, 627-636.	4.0	16
136	Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies Journal of Experimental Medicine, 1991, 173, 37-48.	8.5	191
137	B cells on the podium: regulatory roles of surface and secreted immunoglobulins. Trends in Immunology, 1988, 9, 300-303.	7.5	23
138	EFFECT OF CYCLOSPORINE ON THE ANTIGEN-PRESENTING FUNCTION OF HUMAN AND MURINE ACCESSORY CELLS1. Transplantation, 1988, 46, 40S-43S.	1.0	17
139	Selective Cooperation between T and B Clones Specific for the Same Macromolecular Antigen: Does Antibody Specificity Influence Antigen Processing?. , 1988, , 235-245.		0
140	Constraints in T-B cooperation related to epitope topology onE. coli β-galactosidase. I. The fine specificity of T cells dictates the fine specificity of antibodies directed to conformation- dependent determinants. European Journal of Immunology, 1985, 15, 345-350.	2.9	97
141	The serum capacity to solubilize immune complexes (ICSC) measured by an enzyme-anti-enzyme complex probe. Journal of Immunological Methods, 1985, 77, 119-130.	1.4	1